Your browser doesn't support javascript.
loading
Skin sensitization in silico protocol.
Johnson, Candice; Ahlberg, Ernst; Anger, Lennart T; Beilke, Lisa; Benigni, Romualdo; Bercu, Joel; Bobst, Sol; Bower, David; Brigo, Alessandro; Campbell, Sarah; Cronin, Mark T D; Crooks, Ian; Cross, Kevin P; Doktorova, Tatyana; Exner, Thomas; Faulkner, David; Fearon, Ian M; Fehr, Markus; Gad, Shayne C; Gervais, Véronique; Giddings, Amanda; Glowienke, Susanne; Hardy, Barry; Hasselgren, Catrin; Hillegass, Jedd; Jolly, Robert; Krupp, Eckart; Lomnitski, Liat; Magby, Jason; Mestres, Jordi; Milchak, Lawrence; Miller, Scott; Muster, Wolfgang; Neilson, Louise; Parakhia, Rahul; Parenty, Alexis; Parris, Patricia; Paulino, Alexandre; Paulino, Ana Theresa; Roberts, David W; Schlecker, Harald; Stidl, Reinhard; Suarez-Rodrigez, Diana; Szabo, David T; Tice, Raymond R; Urbisch, Daniel; Vuorinen, Anna; Wall, Brian; Weiler, Thibaud; White, Angela T.
Afiliación
  • Johnson C; Leadscope, Inc, 1393 Dublin Rd, Columbus, OH, 43215, USA. Electronic address: cjohnson@leadscope.com.
  • Ahlberg E; Bioinformatics Department, The University of Uppsala, 752 36, Uppsala, Sweden.
  • Anger LT; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
  • Beilke L; Toxicology Solutions Inc., San Diego, CA, USA.
  • Benigni R; Alpha-PreTox, Via G.Pascoli 1, 00184, Roma, Italy.
  • Bercu J; Gilead Sciences, 333 Lakeside Drive, Foster City, CA, USA.
  • Bobst S; Toxsci Advisors LLC, 2016 Main Suite 1901, Houston, TX, USA.
  • Bower D; Leadscope, Inc, 1393 Dublin Rd, Columbus, OH, 43215, USA.
  • Brigo A; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Campbell S; Nelson Laboratories, LLC, 6280 South Redwood Road, Salt Lake City, UT, 84123, USA.
  • Cronin MTD; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK.
  • Crooks I; British American Tobacco, Research and Development, Regents Park Road, Southampton, Hampshire, SO15 8TL, UK.
  • Cross KP; Leadscope, Inc, 1393 Dublin Rd, Columbus, OH, 43215, USA.
  • Doktorova T; Edelweiss Connect GmbH, Technology Park Basel, Hochbergerstrasse 60C, CH-4057, Basel / Basel-Stadt, Switzerland.
  • Exner T; Edelweiss Connect GmbH, Technology Park Basel, Hochbergerstrasse 60C, CH-4057, Basel / Basel-Stadt, Switzerland.
  • Faulkner D; Chemical Sciences Division, Lawrence Berkeley National Lab, USA.
  • Fearon IM; whatIF? Consulting Ltd, The Crispin Burr Street, Harwell, OX11 0DT, UK.
  • Fehr M; DSM Nutritional Products, Kaiseraugst, Switzerland.
  • Gad SC; Gad Consulting Services, 4008 Barrett Drive, Suite 201, Raleigh, NC, 27609, USA.
  • Gervais V; Servier Group, 905 Route de Saran, 45520, Gidy, France.
  • Giddings A; GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom.
  • Glowienke S; Novartis Pharma AG, Pre-Clinical Safety, Werk Klybeck, CH-4057, Basel, Switzerland.
  • Hardy B; Edelweiss Connect GmbH, Technology Park Basel, Hochbergerstrasse 60C, CH-4057, Basel / Basel-Stadt, Switzerland.
  • Hasselgren C; Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
  • Hillegass J; Bristol-Myers Squibb, Drug Safety Evaluation, 1 Squibb Dr, New Brunswick, NJ, 08903, USA.
  • Jolly R; Toxicology Division, Eli Lilly and Company, Indianapolis, IN, USA.
  • Krupp E; Sanofi, Corporate HSE, Global Product Steweardship, Industriepark Hoechst, D-65926, Frankfurt Am Main, Germany.
  • Lomnitski L; Perrigo Israel Pharmaceuticals Ltd, Shoham, Israel.
  • Magby J; Colgate-Palmolive Technology Center, 909 River Road, Piscataway, NJ, 08855, USA.
  • Mestres J; IMIM Hospital Del Mar Institute of Medical Research and University Pompeu Fabra, Doctor Aiguader 88, Parc de Recerca Biomèdica, 08003 Barcelona, Spain; and Chemotargets SL, Baldiri Reixac 4, Parc Científic de Barcelona, 08028, Barcelona, Spain.
  • Milchak L; 3M Company, St. Paul, MN, USA.
  • Miller S; Leadscope, Inc, 1393 Dublin Rd, Columbus, OH, 43215, USA.
  • Muster W; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
  • Neilson L; Broughton Nicotine Services, Oak Tree House, West Craven Drive, Earby, Lancashire, BB18 6JZ, UK.
  • Parakhia R; Church & Dwight Co., Inc, 469 North Harrison Street, Princeton, NJ, 08543, USA.
  • Parenty A; Novartis Pharma AG, Pre-Clinical Safety, Werk Klybeck, CH-4057, Basel, Switzerland.
  • Parris P; Pfizer Worldwide Research and Development, Sandwich, UK.
  • Paulino A; ORO AGRI Europe, S.A, Palmela, Portugal.
  • Paulino AT; ORO AGRI Europe, S.A, Palmela, Portugal.
  • Roberts DW; Nelson Laboratories, LLC, 6280 South Redwood Road, Salt Lake City, UT, 84123, USA.
  • Schlecker H; Bayer AG, Research & Development, Pharmaceuticals, Industrial Chemicals Toxicology & Genetic Toxicology, 42096, Wuppertal, Germany.
  • Stidl R; Safetree Consulting e.U, Vienna, Austria.
  • Suarez-Rodrigez D; FStox Consulting LTD, 2 Brooks Road, Raunds, Wellingborough, NN9 6NS, UK.
  • Szabo DT; PPG Industries, Pittsburgh, PA, 15146, USA.
  • Tice RR; RTice Consulting, Hillsborough, NC, 27278, USA.
  • Urbisch D; BASF SE, Product Safety, Carl-Bosch-Strasse 38, 67056, Ludwigshafen Am Rhein, Germany.
  • Vuorinen A; DSM Nutritional Products, Kaiseraugst, Switzerland.
  • Wall B; Colgate-Palmolive Technology Center, 909 River Road, Piscataway, NJ, 08855, USA.
  • Weiler T; Servier Group, 905 Route de Saran, 45520, Gidy, France.
  • White AT; GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, United Kingdom.
Regul Toxicol Pharmacol ; 116: 104688, 2020 Oct.
Article en En | MEDLINE | ID: mdl-32621976
ABSTRACT
The assessment of skin sensitization has evolved over the past few years to include in vitro assessments of key events along the adverse outcome pathway and opportunistically capitalize on the strengths of in silico methods to support a weight of evidence assessment without conducting a test in animals. While in silico methods vary greatly in their purpose and format; there is a need to standardize the underlying principles on which such models are developed and to make transparent the implications for the uncertainty in the overall assessment. In this contribution, the relationship between skin sensitization relevant effects, mechanisms, and endpoints are built into a hazard assessment framework. Based on the relevance of the mechanisms and effects as well as the strengths and limitations of the experimental systems used to identify them, rules and principles are defined for deriving skin sensitization in silico assessments. Further, the assignments of reliability and confidence scores that reflect the overall strength of the assessment are discussed. This skin sensitization protocol supports the implementation and acceptance of in silico approaches for the prediction of skin sensitization.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alérgenos / Medición de Riesgo / Haptenos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Regul Toxicol Pharmacol Año: 2020 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Alérgenos / Medición de Riesgo / Haptenos Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Regul Toxicol Pharmacol Año: 2020 Tipo del documento: Article